rg1

Ginsenoside Rg1 (Panaxoside Rg1) is a class of steroid glycosides, and triterpene saponins found exclusively in the plant genus Panax (ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

Ginsenoside Rg1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rg1. Ginsenoside Rg1 (Panaxoside Rg1) is a class of steroid glycosides, and triterpene saponins found exclusively in the plant genus Panax (ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).

RG14620 (Tyrphostin RG14620) is an epidermal growth factor receptor (EGFR) inhibitor.

BRM/BRG1 ATP Inhibitor-1 is an allosteric dual Brahma homolog (BRM)/SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and BRG1/SMARCA4 ATPase activity inhibitor (IC50s<0.005 μM).

PROTAC BRM/BRG1 degrader-4 (example 047) is a potent degrader targeting both BRM and BRG1, demonstrating DC50 values of 0.21 nM and 3.4 nM respectively in SW1573 cells.

PROTAC BRM/BRG1 degrader-2 (Example.004) is a potent PROTAC BRM/BRG1 degrading agent exhibiting a DC50 of less than 10 nM and an IC50 of 15 nM in A549 cells.

BRM/BRG1 ligand 3 is a target protein ligand utilized in the synthesis of PROTAC BRM/BRG1 degrader-3.

BRM/BRG1 Ligand 1 is a BRM/BRG1 ligand utilized for the synthesis of PROTAC BRM/BRG1 degrader-1.

PROTAC BRM/BRG1 degrader-1 is a chemical compound that acts as a degrader of PROTAC BRM/BRG1, exhibiting a DC50 range of 10-100 nM (BRM) and > 1 μM (BRG1). This compound is utilized in cancer research.

BRM/BRG1 ligand 2 serves as a target protein ligand for the synthesis of PROTAC BRM/BRG1 degrader-2.

PROTAC BRM/BRG1 degrader-3 (compound 304) is a PROTAC-based degrader of BRM/BRG1. In SW1573 cells, it degrades BRM with a DC50 of less than 1 nM and BRG1 with a DC50 greater than 1 nM. PROTAC BRM/BRG1 degrader-3 exhibits antitumor activity and inhibits the proliferation of A549 cells with an IC50 of 0.6 nM.

RG108 (N-Phthalyl-L-tryptophan) is a DNA methyltransferase inhibitor with an IC50 of 115 nM.

(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.

[Des-Arg10]-HOE I40 TFA is a potent antagonist of the bradykinin B1 receptor.

ARG1-IN-1 is a human arginase 1 inhibitor with an IC 50 of 29 nM.

BRM/BRG1 ATP Inhibitor-2 is a BRG1/BRM ATPase inhibitor, suitable for studies on the treatment of BAF-related disorders.

BRG1-IN-1 (Compound 11d) is a potent BRG1 inhibitor that surpasses PFI-3 in sensitizing GBM cells to the antiproliferative and cell death-inducing effects of Temozolomide in vitro, and enhances Temozolomide's inhibitory effect on subcutaneous GBM tumor growth[1].

BRM/BRG1 ATP Inhibitor-3 is a potent inhibitor targeting both BRM and BRG1 components of the BAF complex, with IC50 values of 10.4 nM for BRM and 19.3 nM for BRG1, and holds potential for research in cancer and BAF complex-related disorders.

BRM/BRG1 ATP Inhibitor-4, a potent inhibitor of BRG1/BRM, is utilized in the research of cancers and BAF complex-related disorders.

[Arg14,Lys15]Nociceptin TFA is a potent and selective agonist for the NOP receptor (ORL1; OP4), with an EC50 of 1 nM. It shows significant selectivity against opioid receptors, with IC50 values of 0.32 nM for NOP, and 280, >10000, and 1500 nM for μ, δ, and κ receptors, respectively [1].

(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P is a neuropeptide Substance P antagonist [1].

(D-Arg1, D-Pro2, D-Phe7, D-His9)-Substance P is a selective NK1 receptor antagonist [1].

IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research.